

IMPACT OF STRESS RESPONSE IN DEVELOPMENT OF FIRST-EPIISODE PSYCHOSIS IN SCHIZOPHRENIA: AN OVERVIEW OF SYSTEMATIC REVIEWS

Linda Rossini Gajsak¹, Andrea Gelemanovic², Martina Rojnic Kuzman³ & Livia Puljak⁴

¹Neuropsychiatric Hospital Dr. Ivan Barbot, Popovaca, Croatia

²University of Split, School of Medicine, Split, Croatia

³Zagreb School of Medicine and University Hospital Center Zagreb, Zagreb, Croatia

⁴Laboratory for Pain Research, Cochrane Croatia, University of Split, School of Medicine, Split, Croatia

received: 10.01.2017;

revised: 15.02.2017;

accepted: 22.02.2017

SUMMARY

Background: To summarize all available evidence from systematic reviews about the impact of stress response in development of first-episode psychosis (FEP) in schizophrenia.

Methods: An overview of systematic reviews of any type of primary studies was performed. An electronic search of five databases was conducted in February 2017 (CDSR, DARE, Embase, MEDLINE and PsychINFO). Quality of included systematic reviews was assessed using the AMSTAR checklist.

Results: Eight systematic reviews were included. The main findings of the included reviews point out a possible alteration of the stress response in a subgroup of persons with proneness to psychosis. However, the evidence is limited by the inadequate quality of studies, as well as lack of standardization of outcomes and assessment methods.

Conclusions: Given the heterogeneity of current results, there is no solid evidence for uniform alterations of stress response found in persons with FEP in suggestive of schizophrenia that may serve as a marker of vulnerability to stress and possibly proneness to psychotic state in response to daily hassles.

Key words: cortisol – hydrocortisone – stress - first-episode psychosis - schizophrenia

* * * * *

INTRODUCTION

Schizophrenia is a chronic, recurrent disease that usually starts with a first psychotic episode and continues with periods of remission and acute psychosis.

While treatment response is achieved for up to 90% of persons with the first-episode psychosis (FEP) by the end of the first years of treatment, due to treatment non-adherence, the majority of patients relapse within a few years (Emsley 2013). Thus, over its course, schizophrenia still remains a disorder with low functional recovery rates (Jaaskelainen et al. 2013, Wunderink et al. 2013) and it is associated with poor quality of life in patients and their families (Wittchen et al. 2011).

While the pathogenesis of schizophrenia is still largely unknown, a large body of genetic studies concluded that schizophrenia results from the gene x environment interaction (or epigenetic effects on the genome) (van Os & Kapur 2009). This once again revitalized the stress diathesis model of schizophrenia. This model implies that interaction of genes and environmental influences, including a variety of biological/chemical factors (infections, diseases), psychological stressors (mother-infant relationship, family dynamics, life events, childhood trauma) and social factors (society, migration) shape the vulnerability to schizophrenia (Bale et al. 2010, Beards et al. 2013, Holtzman et al. 2013, Van Winkel et al. 2010, Zannas & West 2014).

Stress response implies the activation of the hypothalamus-pituitary-adrenal (HPA) axis, which is activated by the release of corticotropin-releasing hormone (CRH) and of vasopressin (AVP), synthesized in the hypothalamus, which activate the secretion of adrenocorticotrophic hormone (ACTH) from the pituitary, which finally stimulates secretion of cortisol from the adrenal gland. Cortisol subsequently initiates cascade effects in a number of systems (immune, neuroendocrine, inflammatory response, etc.). Alterations of stress response are thus reflected in the alterations of the HPA axis, and can be measured by the cortisol response, including cortisol and ACTH levels, non-suppression of cortisol secretion by dexamethasone in the dexamethasone suppression test, and in the dexamethasone/CRH test (Walker 2016).

A significant number of findings in patients with first psychotic episode of schizophrenia could be related to alterations of stress response. These include altered HPA axis functions (Borges et al. 2013, Cullen et al. 2014), increased baseline prolactin (Kahn et al. 2008), alterations in immune system (Miller et al. 2011), genetic expression of inflammatory markers (Gardiner et al. 2013) or neurocognitive dysfunctions (O'Connor et al. 2013) etc. Some of the stress biomarkers may be present even among persons at risk for psychosis (Mizrahi et al. 2012, Pruessner et al. 2013).

Table 1. Example of search strategy on impact of stress in development of psychotic disorders designed for Ovid MEDLINE and conducted on February 9, 2016

1.	exp Hydrocortisone/
2.	cortisol\$.tw.
3.	hydrocortisone.tw.
4.	1 or 2 or 3
5.	exp "Schizophrenia Spectrum and Other Psychotic Disorders"/
6.	first.tw.
7.	5 or 6
8.	(stress or stress response).tw.
9.	exp Stress, Psychological/
10.	8 or 9
11.	(review or review,tutorial or review, academic).pt.
12.	(medline or medlars or embase or pubmed or cochrane).tw,sh.
13.	(scisearch or psychinfo or psycinfo).tw,sh.
14.	(psychlit or psyclit).tw,sh.
15.	cinahl.tw,sh.
16.	((hand adj2 search\$) or (manual\$ adj2 search\$)).tw,sh.
17.	(electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
18.	(pooling or pooled or mantel haenszel).tw,sh.
19.	(peto or dersimonian or der simonian or fixed effect).tw,sh.
20.	(retraction of publication or retracted publication).pt.
21.	meta-analysis.pt.
22.	meta-analysis.sh.
23.	(meta-analys\$ or meta analys\$ or metaanalys\$).tw,sh.
24.	(systematic\$ adj5 review\$).tw,sh.
25.	(systematic\$ adj5 overview\$).tw,sh.
26.	(quantitativ\$ adj5 review\$).tw,sh.
27.	(quantitativ\$ adj5 overview\$).tw,sh.
28.	(quantitativ\$ adj5 synthesis\$).tw,sh.
29.	(methodologic\$ adj5 review\$).tw,sh.
30.	(methodologic\$ adj5 overview\$).tw,sh.
31.	(integrative research review\$ or research integration).tw.
32.	or/22-31
33.	4 and 7 and 10 and 32

Several systematic reviews attempted recently to summarize the current knowledge about the stress response impact in the development of first psychotic episode. The main findings of the reviews point out a possible alteration of the stress response, reflected by alterations of cortisole and ACTH blood levels in response to stress or pituitary volume (Aiello et al. 2012, Borges et al. 2013). However, in the majority of reviews, conflicting findings were reported as well (Borges et al. 2013, Ciufolini et al. 2014, Girshkin et al. 2014).

The aim of this study was to conduct an overview of all those systematic reviews in order to ascertain the role of the vulnerability to stress in the development of first psychotic episode, to provide recommendations for practice and to identify knowledge gaps that will guide further research.

METHODS

Study protocol

A protocol for this overview of systematic reviews was developed *a priori* and registered in the PROSPERO International Prospective Register of Systematic Reviews (No. CRD42016042155).

Literature search

The search was performed to find relevant studies from the five databases, including Cochrane Database of Systematic Reviews (CDSR), Database of Reviews of Effects (DARE), Embase, MEDLINE and PsychINFO. Each database was searched from its inception to February 9, 2017. A complex search strategy was crea-

ted encompassing search terms related to hydrocortisone, cortisol, stress and stress response, combined with key words for schizophrenia spectrum and other psychotic disorders. Search strategy was created for MEDLINE first (Table 1) and then adapted for other databases. The search was restricted to peer-reviewed journals and English language. Search strategy was very wide on purpose, in order to include all systematic reviews on association between stress, levels of cortisol and psychotic disorders.

Eligibility criteria

Types of studies

We included systematic reviews of any type of primary studies. Systematic reviews that were done by one author only or were using only one database for article search, were discarded as they do not meet the requirements of systematic review.

Participants and outcomes

We included systematic reviews that assessed impact of stress in the development of FEP in schizophrenia spectrum disorders according to the criteria of ICD-10 or DSM-IV or DSM-5.

Study selection

One author (LP) conducted the searches; two authors independently (LRG and AG) screened all retrieved bibliographic records against the inclusion criteria.

Potentially eligible systematic reviews were analyzed in full text by two authors (LRG and AG) independently. A third (LP) and the fourth author (MRK) were consulted in cases of disagreement.

Data extraction and management

A data collection form was developed and tested prior to starting the review. Two authors (LRG and AG) extracted the data independently and compared results afterwards. Disagreements were resolved by a third author (LP). Data extracted included review details (author, title and publication year), review aims, inclusion/exclusion criteria, date of last search and main findings about the impact of stress in development of the first psychotic episode. Authors of the included reviews were not contacted for further information. Data were presented narratively and in tabular form. For systematic reviews that included patients with more than one disease, only data regarding schizophrenia patients were reported. Articles with one author and only one database searched were excluded due to lack of systematic reviewing norms.

Quality assessment of included systematic reviews

Two authors (LRG and AG) independently assessed the methodological quality of the included systematic reviews using the AMSTAR checklist (Shea 2007). Disagreements regarding AMSTAR score were resolved by discussion or a decision made by a third author (LP).




Figure 1. Search strategy flowchart, according to PRISMA guidelines

RESULTS

Literature search

Initial database searching yielded 834 bibliographic records. After deletion of duplicates and screening of titles and abstracts, 35 full texts were analyzed, of which eight met all the inclusion criteria (Aiello et al. 2012, Berger et al. 2016, Borges et al. 2013, Chaumette et al. 2015, Ciufolini et al. 2014, Fond et al. 2015, Girshkin et al. 2014, Lange et al. 2016) and 27 were excluded with reasons (Table 2). The study selection process is presented in Figure 1.

Characteristics of included systematic reviews

All included systematic reviews were published recently, between 2012 and 2016, and the main characteristics of each included systematic reviews are summarized in Table 3. Inclusion criteria were slightly different among the selected systematic reviews: some explicitly indicated that included patients suffered from first-episode psychosis (Borges et al. 2013, Chaumette et al. 2015, Ciufolini et al. 2014, Fond et al. 2015); others only stated schizophrenia, but considering the use of different classification we considered them also to be relevant (Aiello et al. 2012, Borges et al. 2013, Ciufolini et al. 2014, Girshkin et al. 2014). Even though our primary idea was to identify adult-based studies, one systematic review also included studies with patients above 15 years of age (Chaumette et al. 2015). Only two systematic reviews did not specify their exclusion criteria (Aiello et al. 2012, Fond et al. 2015), while others had similar exclusion criteria, including studies with already published samples, physical illness, naturalistic stressors, metabolically demanding tasks, studies with imaging tasks, or with reactivity to stress, urinary cortisol measures, comments, abstracts and reviews. Half of the included systematic reviews had also performed a meta-analysis (Berger et al. 2016, Chaumette et al. 2015, Ciufolini et al. 2014, Girshkin et al. 2014). Other main characteristics of each included systematic review are shown in Table 3.

Main findings of included systematic reviews

Aiello et al. analyzed stress abnormalities in individuals at risk of psychosis. They reported that relatives of patients with schizophrenia had increased ACTH blood levels in response to stress and increased pituitary volume, whereas from three studies on cortisol level after stress exposure in relatives only one found increased cortisol levels. Studies on pituitary volume showed that HPA axis hyperactivity is already present before the onset of psychosis in patients with ultra-high risk for psychosis (UHR-P) compared to controls (ultra-high risk who did not convert to psychosis, UHR-NP). Studies on hippocampus showed that some authors noticed a hippocampal volume increase in participants who made the transition to psychosis, despite the

increased activity in the same participants. This review concluded that enhanced response of HPA axis to stress may be part of biological vulnerability to psychosis, which is present already before the psychosis onset (Aiello et al. 2012).

Berger et al. investigated cortisol awakening response (CAR) among the patients along the psychosis continuum including schizophrenia, first-episode psychosis, and at-risk mental states (ARMS) compared to healthy controls. Flattened CAR was found in patients with schizophrenia and first-time psychosis, but not in those at-risk. The authors conclude that CAR may be important marker for transition risk, but warn about methodological problems in included studies, such as small number of studies, small sample sizes and different scales being used for scoring symptom severity (Berger et al. 2016).

Borges et al. reported that 6 primary studies on cortisol levels found higher plasma cortisol levels when comparing patients with FEP with healthy controls, while 4 studies showed no significant difference. Studies on pituitary volume showed that 4 studies reported a larger pituitary volume comparing FEP with healthy controls, while 5 studies showed no significant difference. Additionally, 2 studies showed that longer duration of psychosis was associated with a reduction in pituitary volume, while 3 studies showed that prolactin-enhanced antipsychotics were associated with larger pituitary volume. They concluded that patients with FEP exhibit specific pattern of HPA axis hyperactivity, as evidenced by higher baseline cortisol levels compared to controls, blunted cortisol awakening response and enlarged pituitary on MRI scan (Borges et al. 2013).

Chaumette et al. showed no significant difference in cortisol levels in the first French cohort of young help-seekers (ICAAR, *Influence du Cannabis sur l'émergence de symptômes psychopathologiques des Adolescents et jeunes Adultes présentant un état mental à Risque*) or when comparing FEP with control group. Studies on cortisol levels in UHR showed slightly higher salivary cortisol level at baseline than healthy controls. Their meta-analysis revealed a significantly higher salivary basal cortisol levels in UHR compared to controls, but none between FEP and controls or UHR and FEP. They warn that their results indicate that basal levels of cortisol may not be used as a reliable biomarker of early psychosis (Chaumette et al. 2015).

Ciufolini et al. included three studies with individuals with schizophrenia and used meta-analysis to investigate HPA axis response to social stress. The results showed that subjects with schizophrenia have lower cortisol levels in preparation and during the tasks of the stress response tests (Ciufolini et al. 2014).

Fond et al. showed that multiple studies reported a basal hyperactivity of the HPA axis in male patients with FEP and that it may be correlated with disease severity. Also, it was found that antipsychotics can normalize diurnal cortisol hypersecretion, but they did not blunt cortisol awakening response in FEP (Fond et al. 2015).

Table 2. List of excluded studies after full text screening, with reasons

Author	Title	Reason for exclusion*
Aguero-Tejado 2014	Short polymorphism of the serotonin transporter (5-HTTLPR) gene and its association with the cortisol stress response: A meta-analysis	Wrong outcome
Alexander et al. 2014	DNA methylation profiles within the serotonin transporter gene moderate the association of 5-HTTLPR and cortisol stress reactivity	Wrong outcome
Baumeister et al. 2014	The interface of stress and the HPA axis in behavioural phenotypes of mental illness	Wrong study type
Belvederi Murri et al. 2016	The HPA axis in bipolar disorder: Systematic review and meta-analysis	Wrong phenotype
Birkett 2011	The Trier Social Stress Test protocol for inducing psychological stress	Not relevant
Bradley & Dinan 2010	A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality	Wrong study type
Chaumette et al. 2016	Stress and psychotic transition: A literature review	Narrative review (not systematic review); not in English
Chida & Steptoe 2009	Cortisol awakening response and psychosocial factors: A systematic review and meta-analysis	Wrong phenotype
Dickerson & Kemeny 2004	Acute stressors and cortisol responses: A theoretical integration and synthesis of laboratory research	Wrong phenotype
Egliston et al. 2007	Stress in pregnancy and infant HPA axis function: Conceptual and methodological issues relating to the use of salivary cortisol as an outcome measure	Wrong phenotype
Hellhammer 2011	The Trier Social Stress Test (TSST) - A valid tool for clinical studies	Not relevant
Hjortskov et al. 2004	Evaluation of salivary cortisol as a biomarker of self-reported mental stress in field studies	Wrong phenotype
Jansen et al. 2010	Cortisol reactivity in young infants	Wrong phenotype
Jessop & Turner-Cobb 2008	Measurement and meaning of salivary cortisol: A focus on health and disease in children	Wrong phenotype
Karanikas & Garyfallos 2015	Role of cortisol in patients at risk for psychosis mental state and psychopathological correlates: A systematic review	Wrong study type
Karanikas et al. 2014	The role of cortisol in first episode of psychosis: a systematic review	Wrong study type
Kirschbaum & Hellhammer 1994	Salivary cortisol in psychoneuroendocrine research: Recent developments and applications	Wrong study type
Miller et al. 2007	If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans	Wrong phenotype
Miller et al. 2013	The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: A meta-analysis	Wrong outcome
Nordholm et al. 2013	Pituitary gland volume in patients with schizophrenia, subjects at ultra high risk of developing psychosis and healthy controls: A systematic review and meta-analysis	Wrong outcome
Stalder et al. 2017	Stress-related and basic determinants of hair cortisol in humans: A meta-analysis	Wrong phenotype
Staufenbiel et al. 2013	Hair cortisol, stress exposure, and mental health in humans: A systematic review	Wrong phenotype
Tanaka & Naruishi 2008	Development of an on-site measurement system for salivary stress-related substances based on microchip capillary electrophoresis technology	Not relevant
Van Andel et al. 2014	Salivary cortisol: A possible biomarker in evaluating stress and effects of interventions in young foster children?	Wrong phenotype
Van Winkel et al. 2013	Childhood trauma as a cause of psychosis: Linking genes, psychology, and biology	Wrong outcome
Volko et al. 2016	Model approach for stress induced steroidal hormone cascade changes in severe mental diseases	Wrong phenotype
Zorn et al. 2017	Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis	Wrong study type

* Definition of exclusion criteria:

Wrong outcome: effect of gene polymorphism on cortisol and stress response/volume of pituitary volume gland and onset of psychosis/childhood trauma and psychosis;

Wrong phenotype: cortisol response in bipolar disorder/first psychotic episode not specified/healthy individuals/children/infants/prenatally stressed women/self-reported mental stress at the work place;

Wrong study type: not systematic review (articles with one author; only one database searched);

Not relevant: TSST protocol/measurement system for salivary stress-related substances.

Table 3. Study characteristics of included systematic reviews

Study, year	Search date	Databases	N of studies	N of participants	Age of participants	Outcome
Aiello et al. 2012	2002 - Apr 2012	PubMed, The Cochrane Library, Scopus, Embase, Ovid of Medline, PsychINFO, ISI web of Knowledge	44*	1458 relatives 1314 patients 847 prodromal subjects 1946 controls	not reported	stress response (cortisol level, ACTH level), pituitary volume, hippocampal volume
Berger et al. 2016	up to July 2015	MEDLINE, Scopus, PsycINFO, Web of Science	11	394 cases 398 controls	13-41 years	cortisol awakening response
Borges et al. 2013	1985 - Oct 2012	PubMed, PsychINFO, Ovid of Medline, The Cochrane Library	27**	889 cases 907 controls	not reported	cortisol level, pituitary volume
Chaumette et al. 2015	up to June 2015	Medline, Web of Knowledge (including Web of Science), EBSCO (including Academic Search Premier, PASCAL, PsycARTICLES, Psychology, Behavioral Sciences Collection), Clinical Trials database	13***	818 cases 631 controls	15-30 years (ICAAR cohort)	cortisol level
Ciufolini et al. 2014	1993 - Aug 2013	PubMed, PsychINFO	3	59 cases 65 controls	19-39 years (mean 26.3)	cortisol level
Fond et al. 2015	up to Sep 2014	The Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Medline Unindexed, EMBASE, PsycINFO, Google Scholar	not clear	not clear	not reported	hormonal biomarkers, peripheral monoamines and metabolites blood or urine levels, biomarkers of immune inflammation and oxidative stress, candidate genes polymorphisms
Girshkin et al. 2014	up to June 2014	MEDLINE, Embase, BIOSIS Previews	44	1520 cases 1093 controls	20-52 years (mean 28)	cortisol level
Lange et al. 2016	Jan 1993 - Aug 2015	PubMed, Web of Knowledge	11	420 patients and 337 controls	22-41 years	subjective responses to psychosocial stress; HPA axis response

* stress response: 11 studies with 788 participants (228/147/180/233); pituitary volume: 5 studies with 617 participants (182/107/130/198); hippocampal volume: 28 studies with 4160 participants (1048/1060/537/1515)

** cortisol level: 16 studies with 849 participants (473/376); pituitary volume: 11 studies with 947 participants (416/531)

*** UHR (ultra-high risk individuals): 7 studies identified through database search + data from ICAAR cohort (603/457); FEP: 5 studies identified through database search + data from ICAAR cohort (215/226);

ICAAR cohort: 93 ultra-high risk individuals/52 help-seekers controls/24 individuals with first episode of psychosis

Table 4. AMSTAR score on methodological quality of the included systematic reviews

Study, year	AMSTAR domains											Total score
	1	2	3	4	5	6	7	8	9	10	11	
Aiello et al. 2012	0	0	1	0	0	1	0	0	0	0	0	2
Berger et al. 2016	0	1	1	0	0	1	1	0	1	0	0	5
Borges et al. 2013	0	0	1	0	0	1	0	0	0	0	0	2
Chaumette et al. 2015	0	0	1	0	0	1	0	0	1	0	0	3
Ciufolini et al. 2014	0	1	1	0	0	1	0	0	1	0	0	4
Fond et al. 2015	0	0	1	0	0	1	0	0	0	0	1	3
Girshkin et al. 2014	0	1	1	1	0	1	1	1	1	1	0	8
Lange et al. 2016	1	0	1	0	1	1	0	0	0	0	0	4

Girshkin et al. conducted a meta-analysis that showed a slight increase in morning cortisol levels in schizophrenia when compared to healthy controls, but with significant heterogeneity among studies. Subgroup analyses revealed bigger effect sizes in schizophrenia when compared to FEP, but neither age nor sex were found to be significant confounders. However, bigger increase in morning cortisol level was observed in those sampled before 8 am, and medication

status was also found to be significantly associated with morning cortisol levels in people with schizophrenia (*Girshkin et al. 2014*).

Lange et al. analyzed emotional and endocrinological response to experimentally induced psychosocial stress in patients with schizophrenia spectrum disorder (SSD). They reported that first-onset medication naïve SSD patients may show differences in subjective responses to stress measures and cortisol release,

unlike chronically ill SSD patients, which could be a correlate of pathophysiological dysfunction of the HPA axis prior or at the onset of SSD (Lange et al. 2016).

Quality assessment of included systematic reviews

AMSTAR score on the methodological quality of each included systematic reviews is shown in Table 4. Overall, the methodological quality of included systematic reviews was inadequate, with 4 reviews of low quality, 3 reviews of medium quality and 1 review of high quality. Only one of the reviews reported having *a priori* defined protocol, which was registered in PROSPERO (Lange et al. 2016). The majority of the reviews did not report a list of both included and excluded studies or analyze quality of included studies (Table 4).

Conflict of interest in included systematic reviews

None of the 8 systematic reviews was funded by for-profit industry; all of them were funded by various non-profit governmental and non-governmental organizations. Authors of 6 systematic reviews reported having no conflict of interest (Aiello et al. 2012, Berger et al. 2016, Borges et al. 2013, Chaumette et al. 2015, Girshkin et al. 2014, Lange et al. 2016). Authors of two systematic reviews reported having different ties with pharmaceutical industry as potential conflict of interest (Ciufolini et al. 2014, Fond et al. 2015).

DISCUSSION

The current overview included 8 systematic reviews about the role of stress in the onset of schizophrenia published between 2012 and 2016, of overall inadequate methodological quality.

The main findings of the reviews point out a possible alteration of the stress response, in a subgroup of persons with psychosis proneness. This is observable even before the onset of psychosis in persons at risk suggested by: (i) increased ACTH blood levels in response to stress and increased pituitary volume in relatives of patients with schizophrenia (Aiello et al. 2012), and (ii) a significantly higher salivary basal cortisol levels in patients with ultra-high risk for psychosis compared to controls (Chaumette et al. 2015). Compared to controls, in persons in whom transition to psychosis occurs, increased hippocampal volume (Aiello et al. 2012), higher plasma cortisol levels (Borges et al. 2013) larger pituitary volume (Borges et al. 2013), as well as a basal hyperactivity of the HPA axis (in males only) (Fond et al. 2015) was found. However, in the majority of reviews, conflicting findings were reported as well (Borges et al. 2013, Ciufolini et al. 2014, Girshkin et al. 2014), or authors reported no differences between FEP and controls (Borges et al. 2013). One review found that patients along the psychosis-continuum have a blunted CAR

compared to healthy controls, and further subgroup analysis revealed that this difference is only present in patients with FEP and schizophrenia but not in individuals at high risk for psychosis (Berger et al. 2016). Together with meta-analysis of cortisol levels in patients with schizophrenia that showed elevated morning cortisol compared to controls (Girshkin et al. 2014) and altered HPA-axis response to psychosocial stress that was characterized by lower anticipation and peak cortisol levels (Ciufolini et al. 2014), this represents strong evidence for dysregulated HPA-axis activity in patients with schizophrenia, characterized by a flat diurnal cortisol curve with overall high cortisol levels, and alterations in HPA-axis reactivity to laboratory-induced psychosocial stress. Another review showed that first-episode, medication naive patients with SSD experience more anxiety and less control during the task than healthy controls and seem to be more disposed to a subjective responses to stress reaction compared to chronically ill patients (Lange et al. 2016).

Some of the observed inconsistencies may be explained with other factors, primarily relating to the methodology of the studies included in the reviews. These include the lack of standardisation of biological assessment methods of stress response (e.g. blood cortisol, salivary cortisol, hippocampal volume, etc.), different or no psychological assessments of stress response, the lack of assessment of treatment methods (Vives et al. 2015), as well as the lack of standardisation of outcomes (e.g. several psychiatric rating scales, different cut-offs and follow-up periods).

Other factors may include the effects of illness-related factors such as the duration and severity of the symptoms, or the influence of medication on stress response. This may explain a significant heterogeneity of the studies included in some of the reviews. In particular, longer duration of psychosis was associated with a reduction in pituitary volume (Borges et al. 2013), the severity of illness was found to be correlated with the hyperactivity of HPA axis (Fond et al. 2015) and higher basal cortisol levels were found in patients with schizophrenia compared to patients with FEP or controls (Fond et al. 2015). Somatic comorbidities (e.g. chronic illnesses such as diabetes) which may influence stress response as well, were not assessed in the reviews (Wosu et al. 2013).

Lastly, antipsychotic medication, other psychoactive substances, as well as other forms of treatment that may mediate stress response were not systematically assessed in the reviews. For example, prolactin-enhanced antipsychotics were associated with larger pituitary volume (Borges et al. 2013). Anti-inflammatory drugs, which are available over the counter and easily accessible to controls and patients may possibly influence stress response as well (Di Luigi et al. 2007). The use of cannabis, which is quite common among persons with FEP (Marconi et al. 2016), may affect the

levels of salivary cortisol (King et al. 2011, Monteleone et al. 2014). Lastly, treatment with psychotherapies and meditation-like techniques that may alter stress response were not assessed in those studies as well (Jensen et al. 2015, Rosenkranz et al. 2016).

Limitations

The following limitations of this overview were noted: (i) Methodological quality of included systematic reviews was not high. Future systematic reviews should follow relevant checklist for methodological quality to improve quality of evidence from secondary research. (ii) In general, no information on participants that may be relevant for overall stress response were included in the review. These include somatic comorbidities of the patients, the use of anti-inflammatory medication, the use of psychiatric medication, the use of marijuana, the use of alternative or additional treatment, like meditation, yoga, psychotherapy. (iii) Clinically relevant outcomes were not analyzed. First, reviews failed to analyze the association of alterations of biological stress biomarkers (i.e. cortisol) with clinically meaningful findings such as overall vulnerability to stress using scales of stressful events, or scales of daily hassles, stress response to provoking stimuli. Secondly, reviews did not analyze clinical outcomes of longitudinal studies that assess stress response in different state of the FEP (at risk, acute psychosis, remission of symptoms, functional remission) and different state of treatment (i.e., psychotherapy, medications such as antipsychotics).

Clinical implications

The aim of this review was to ascertain whether alterations of stress response found in persons at risk for schizophrenia and FEP may serve as a marker that may predict psychotic episodes and serve as a biological marker of treatment response, and serve as a treatment tool in clinical practice.

However, given the heterogeneity of current results, there is no solid evidence for uniform alterations of stress response found in persons with FEP that may serve as a marker of vulnerability to stress and possibly proneness to psychotic state in response to daily hassles.

Implications for future research

Given the initial aims of the review, as well as the current limitations of this overview, future systematic reviews should (i) include systematic reviews that follow relevant checklist for methodological quality to improve quality of evidence from secondary research. (ii) Include studies that analyzed the influence of stress on psychosis with more than one biological marker of stress response (i.e. awakening plasma cortisol, awakening salivary cortisol, cortisol in response to stress stimuli) which could improve reliability of the studies. (iii) All systematic reviews should take into

account the effects of potential factors in the studies that may influence stress response (e.g. marijuana use, drugs, chronic illnesses, etc.). (iv) Include studies that analyze clinical outcomes such as overall vulnerability to stress using scales of stressful events, or scales of daily hassles, stress response to provoking stimuli over a longitudinal period encompassing a different state of the FEP (at risk, acute psychosis, remission of symptoms, functional remission) and different state of treatment (i.e., psychotherapy, medications such as antipsychotics).

Acknowledgements:

This work was funded by the grant of the Croatian Science Foundation (HRZZ) No. UIP-2014-09-1245 "Biomarkers in schizophrenia – integration of complementary methods in longitudinal follow up of first episode psychosis patients".

Conflict of interest: None to declare.

Contribution of individual authors:

Study conception and design: Linda Rossini Gajsak & Livia Puljak;
Acquisition of data, or analysis and interpretation of data: Linda Rossini Gajsak, Andrea Gelemanovic, Martina Rojnic Kuzman & Livia Puljak;
Drafting the article or revising it critically for important intellectual content: Linda Rossini Gajsak, Andrea Gelemanovic, Martina Rojnic Kuzman & Livia Puljak;
Final approval of the version to be published: Linda Rossini Gajsak, Andrea Gelemanovic, Martina Rojnic Kuzman & Livia Puljak.

References

1. Aiello G, Horowitz M, Hepgul N, Pariante CM, Mondelli V: *Stress abnormalities in individuals at risk for psychosis: A review of studies in subjects with familial risk or with "at risk" mental state. Psychoneuroendocrinology* 2012; 37:1600-1613.
2. Bale TL, Baram TZ, Brown AS, Goldstein JM, Insel TR, McCarthy MM, Nemeroff CB, Reyes TM, Simerly RB, Susser ES, Nestler EJ: *Early life programming and neurodevelopmental disorders. Biological psychiatry* 2010; 68:314-319.
3. Beards S, Gayer-Anderson C, Borges S, Dewey ME, Fisher HL, Morgan C: *Life events and psychosis: a review and meta-analysis. Schizophrenia bulletin* 2013; 39:740-747.
4. Berger M, Kraeuter AK, Romanik D, Malouf P, Amminger GP, Sarnyai Z: *Cortisol awakening response in patients with psychosis: Systematic review and meta-analysis. [Review]. Neuroscience & Biobehavioral Reviews* 2016; 68:157-166.
5. Borges S, Gayer-Anderson C, Mondelli V: *A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology* 2013; 38:603-611.

6. Chaumette B, Kebir O, Mam-Lam-Fook C, Morvan Y, Bourgin J, Godsil BP, Plaze M, Gaillard R, Jay TM, Krebs MO: Salivary cortisol in early psychosis: New findings and meta-analysis. *Psychoneuroendocrinology* 2015; 63:262-270.
7. Ciufolini S, Dazzan P, Kempton MJ, Pariante C, Mondelli V: HPA axis response to social stress is attenuated in schizophrenia but normal in depression: evidence from a meta-analysis of existing studies. *Neuroscience & Biobehavioral Reviews* 2014; 47:359-368.
8. Cullen AE, Zunszain PA, Dickson H, Roberts RE, Fisher HL, Pariante CM, Laurens KR: Cortisol awakening response and diurnal cortisol among children at elevated risk for schizophrenia: relationship to psychosocial stress and cognition. *Psychoneuroendocrinology* 2014; 46:1-13.
9. Di Luigi L, Rossi C, Sgro P, Fierro V, Romanelli F, Baldari C, Guidetti L: Do non-steroidal anti-inflammatory drugs influence the steroid hormone milieu in male athletes? *Int J Sports Med* 2007; 28:809-814.
10. Emsley R, Chiliza B, Asmal R, Harvey BH: The nature of relapse in schizophrenia. *BMC Psychiatry* 2013; 13:50.
11. Fond G, d'Albis M-A, Jamain S, Tamouza R, Arango C, Fleischhacker WW, Glenthøj B, Leweke M, Lewis S, McGuire P, Meyer-Lindenberg A, Sommer IE, Winter-van Rossum I, Kapur S, Kahn RS, Rujescu D, Leboyer M: The promise of biological markers for treatment response in first-episode psychosis: A systematic review. [References]. *Schizophrenia Bulletin* 2015; 41:559-573.
12. Gardiner EJ, Cairns MJ, Liu B, Beveridge NJ, Carr V, Kelly B, Scott RJ, Tooney PA: Gene expression analysis reveals schizophrenia-associated dysregulation of immune pathways in peripheral blood mononuclear cells. *Journal of psychiatric research* 2013; 47:425-437.
13. Girshkin L, Matheson SL, Shepherd AM, Green MJ: Morning cortisol levels in schizophrenia and bipolar disorder: a meta-analysis. *Psychoneuroendocrinology* 2014; 49:187-206.
14. Holtzman CW, Trotman HD, Goulding SM, Ryan AT, Macdonald AN, Shapiro DI, Brasfield JL, Walker EF: Stress and neurodevelopmental processes in the emergence of psychosis. *Neuroscience* 2013; 249:172-191.
15. Jaaskelainen E, Juola P, Hirvonen N, McGrath JJ, Saha S, Isohanni M, Veijola J, Miettunen J: A systematic review and meta-analysis of recovery in schizophrenia. *Schizophrenia bulletin* 2013; 39:1296-1306.
16. Jensen CG, Lansner J, Petersen A, Vangkilde SA, Ringkobing SP, Frokjaer VG, Adamsen D, Knudsen GM, Denninger JW, Hasselbalch SG: Open and Calm - A randomized controlled trial evaluating a public stress reduction program in Denmark. *Bmc Public Health* 2015; 15.
17. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Grobbee DE: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* 2008; 371:1085-1097.
18. King GR, Ernst T, Deng WR, Stenger A, Gonzales RMK, Nakama H, Chang LD: Altered Brain Activation During Visuomotor Integration in Chronic Active Cannabis Users: Relationship to Cortisol Levels. *J Neurosci* 2011; 31:17923-17931.
19. Lange C, Deutschenbaur L, Borgwardt S, Lang UE, Walter M, Huber CG: Experimentally induced psychosocial stress in schizophrenia spectrum disorders: A systematic review. [Review]. *Schizophrenia Research* 2016; 09, 09.
20. Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E: Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis. *Schizophrenia bulletin* 2016; 42:1262-1269.
21. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. *Biological psychiatry* 2011; 70:663-671.
22. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA: Increased stress-induced dopamine release in psychosis. *Biological psychiatry* 2012; 71:561-567.
23. Monteleone P, Di Filippo C, Fabrazzo M, Milano W, Martiadis V, Corrivetti G, Monteleone AM, Maj M: Flattened cortisol awakening response in chronic patients with schizophrenia onset after cannabis exposure. *Psychiatry research* 2014; 215:263-267.
24. O'Connor JA, Wiffen B, Diforti M, Ferraro L, Joseph C, Koliakou A, Bonaccorso S, Murray RM, David AS: Neuropsychological, clinical and cognitive insight predictors of outcome in a first episode psychosis study. *Schizophrenia research* 2013; 149:70-76.
25. Pruessner M, Becharad-Evans L, Boekestyn L, Iyer SN, Pruessner JC, Malla AK: Attenuated cortisol response to acute psychosocial stress in individuals at ultra-high risk for psychosis. *Schizophrenia research* 2013; 146:79-86.
26. Rosenkranz MA, Lutz A, Perlman DM, Bachhuber DRW, Schuyler BS, MacCoon DG, Davidson RJ: Reduced stress and inflammatory responsiveness in experienced meditators compared to a matched healthy control group. *Psychoneuroendocrinology* 2016; 68:117-125.
27. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, Porter AC, Tugwell P, Moher D & Bouter LM: Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology*, 2007.
28. van Os J, Kapur S: Schizophrenia. *Lancet* 2009; 374:635-645.
29. Van Winkel R, Esquivel G, Kenis G, Wichers M, Collip D, Peerbooms O, Rutten B, Myin-Germeys I, Van Os J: REVIEW: Genome-wide findings in schizophrenia and the role of gene-environment interplay. *CNS Neurosci Ther* 2010; 16:e185-92.
30. Vives AH, De Angel V, Papadopoulos A, Strawbridge R, Wise T, Young AH, Arnone D, Cleare AJ: The relationship between cortisol, stress and psychiatric illness: New insights using hair analysis. *Journal of psychiatric research* 2015; 70:38-49.
31. Walker FR, Pflingst K, Carnevali L, Sgoifo A, Nalivaiko E: In the search for integrative biomarker of resilience to psychological stress. *Neurosci Biobehav Rev* 2016; pii:S0149-7634(15)30360-2.
32. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC: The size and burden of mental disorders and other disorders of the brain in Europe

2010. *European Neuropsychopharmacology* 2011; 21:655-679.
33. Wosu AC, Valdimarsdottir U, Shields AE, Williams DR, Williams MA: Correlates of cortisol in human hair: implications for epidemiologic studies on health effects of chronic stress. *Ann Epidemiol* 2013; 23:797-811.
34. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ: Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. *JAMA Psychiatry* 2013; 70:913-920.
35. Zannas AS, West AE: Epigenetics and the regulation of stress vulnerability and resilience. *Neuroscience* 2014; 264:157-170.

Correspondence:

Linda Rossini Gajsak, MD
Department of Biological Psychiatry, Neuropsychiatric Hospital Dr. Ivan Barbot
Jelengradska 1, 44314 Popovaca, Croatia
E-mail: lrgajsak@gmail.com